---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-069512"
form_type: "8-K"
ticker: "LABT"
cik: "0002079272"
company_name: "Lakewood-Amedex Biotherapeutics Inc."
filed_at: "2026-06-17T15:40:39+00:00"
generated_at: "2026-06-17T15:42:10.178847+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lakewood-Amedex announces 1-for-10 reverse stock split effective June 19, 2026

## Summary
- Reverse split ratio: 1-for-10; effective at 4:01 p.m. ET on June 19, 2026; trading starts split-adjusted on Nasdaq June 22.
- Outstanding shares reduced from ~17,506,577 to ~1,750,789; fractional shares rounded up to next whole share.
- Authorized shares reduced proportionately to 12,500,000; new CUSIP 51255A201 assigned; ticker LABT unchanged.
- Board unanimously approved the split on June 1, 2026; adjustments made to equity awards, warrants, and preferred stock.
- No stated reason for the split; typical use is to regain Nasdaq minimum bid price compliance.

## SEC filing metadata
- accession: 0001213900-26-069512
- form_type: 8-K
- ticker: LABT
- cik: 0002079272
- company_name: Lakewood-Amedex Biotherapeutics Inc.
- filed_at: 2026-06-17T15:40:39+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/0001213900-26-069512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/ea0294845-8k_lakewood.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-069512
- JSON: https://secwatch.observer/filing/0001213900-26-069512.json
- Plain text: https://secwatch.observer/filing/0001213900-26-069512.txt

## Key facts
- Governance Changes
  Lakewood-Amedex Biotherapeutics Inc.: Filed a Certificate of Change to effectuate a 1-for-10 reverse stock split and reduce authorized shares to 12,500,000 (effective 2026-06-19).
  - Change: charter amendment
  - Effective: 2026-06-19
  source text: On June 15, 2026, Lakewood-Amedex Biotherapeutics Inc (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/0001213900-26-069512-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.